Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
House dust mite allergoid immunotherapy in allergic rhinitis/rhinoconjunctivitis and mild allergic asthma
2006-000934-11Phase 3Completed
- Sponsor
- Allergopharma
- Start
- May 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma comparing House dust mite allergoid with Placebo (2 arms). Primary endpoint: Symptom-Medication-Score diary assessment. Started May 2006; status: completed.
02
Drugs
Acaroid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2006-000934-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000934-11.